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Objectives: Payments for Performance (P4P) schemes are commonly used in 
many OECD countries in order to incite physicians to improve both quality and 
efficiency of prescribing. In France, a set of 29 indicators has been selected as the 
P4P perimeter by National Public Health Insurance. Each indicator provides useful 
information of GPs’ performance, but it is not that easy to combine them all at 
the same time in order to provide a synthetic view of GPs’ performance. Instead, 
some of these indicators can be grouped together according to a therapeutic ration-
ale (diabetes indicators, high blood pressure indicators) or an efficiency rationale 
(multiple-sourced drug prescribing). Data Envelopment Analysis (DEA) can be used 
to calculate an aggregated score for each GP and for each dimension (therapeutic or 
efficiency). MethOds: Database used in this study were taken from the IMS-Health 
Disease Analyzer (DA) database. It contains information on pharmaceutical pre-
scriptions administered by 693 French General Practitioners and related diagnoses. 
Quality and efficiency indicators are calculated both inside and outside P4P perim-
eter. Indicators reflecting efficiency are considered separately from those reflecting 
quality and the latter are grouped according to therapeutic rationale (diabetes, high 
blood pressure). Data Envelopment Analysis (DEA) is used to produce performance 
scores while aggregating several efficiency or quality scores and neutralizing at the 
same time each GP’s characteristics. Results: DEA scores are calculated on each 
dimension (quality or efficiency) and for each GP. Comparing the scores on each 
dimension enables to better understand if GPs’ are faced with a trade-off between 
these two Objectives. cOnclusiOns: Results from this analysis may have implica-
tions for public policy design. A better understanding of GPs’ strategies relatively 
to P4P schemes could enable to adapt incentives in order to improve the system.
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Objectives: Neonates are among special population group who are more 
susceptible to nosocomial infections due to underdeveloped immunity level at 
their age (0-28 days of life) and it is a common practice of administering anti-
biotics, pending bacterial culture results, to sick neonates and to neonates who 
are more prone to develop infectious diseases; which in turn is gradually pro-
gressing towards a global problem of multidrug antibiotic resistance in Neonatal 
Intensive Care Units. Objective of the present study was to study prescribing pat-
terns of antibiotics in hospitalized neonates, and to assess duration of therapy, 
antibiotic regimen and outcome of therapy. MethOds: All neonates prescribed 
with antibiotics during 6 months period from November 2014 to April 2014 were 
selected. A prospective observational study was carried on selected cases by 
using sources of data such as patient treatment charts, progress sheet, labora-
tory investigation reports, and patient discharge summary; collected datas were 
reported in case record forms. Data analysis was done with SPSS (18.0), Microsoft 
Excel (2010). Results: Of the total of 404 admitted neonates, 30% (n = 122) were 
prescribed with antibiotics; among which 76 (62.3%) males and 46 (37.7%) were 
females. Among n= 122 cases, 71 (58.2%) empirically and 51 (41.8%) were pre-
scribed in indication of infections. Most commonly prescribed antibiotic class were 
Aminoglycoside (97.54%), broad spectrum penicillin (66.39%), extended spectrum 
penicillin (28.68%), 2ndgeneration cephalosporin (17.21%). Empirical use of ampi-
cillin and amikacin were most frequently encountered. Our study showed that 
Dual antibiotic regimen produced a better outcome (50%) than single/triple/more 
antibiotic regimen. cOnclusiOns: The broader outcome of this study would be 
the potential utility of this data in designing strategies both at level of physicians 
and administrators for rational prescribing and policy decisions respectively; so 
that a continuous surveillance for rational use of antibiotics and strategy of anti-
biotic cycling can provide some better answers for difficulties coming across in 
management of neonatal infections.
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Objectives: Payments for Performance (P4P) schemes are commonly used 
in many OECD countries in order to incite physicians to improve both quality 
and efficiency of prescribing. In France, a set of 29 indicators has been selected 
as the P4P perimeter by National Public Health Insurance. P4P schemes may 
induce undesirable behaviors from GPs leading to a decrease both in quality and 
efficiency outside the P4P perimeter (De Pouvourville, 2013). On the contrary, 
other studies (Campbell et al., 2009) tend to show that respecting P4P targets 
may imply a virtuous effect outside P4P. MethOds: Database used in this study 
were taken from the IMS-Health Disease Analyzer (DA) database. It contains 
information on pharmaceutical prescriptions administered by 693 French General 
Practitioners and related diagnoses. Quality and efficiency indicators are calcu-
lated both inside and outside P4P perimeter. In a first step, each category –quality 
or efficiency- is considered separately. We calculate an aggregated score for each 
category, by averaging indicators pertaining to it. In a second step, each indicator 
outside the P4P perimeter is regressed on quality or efficiency aggregated scores, 
controlling for other characteristics of the physician. Results: At first sight, 
there is no obvious link between quality and efficiency scores inside and outside 
P4P perimeter. As a matter of fact, descriptive statistics, correlation analysis and 
Principal Component Analysis do not show any straightforward relation. All these 
first results call for further analyses. cOnclusiOns: Results from this analysis 
may have implications for public policy design. If respecting P4P targets imply a 
virtuous effect outside P4P, there is no need to extend the P4P perimeter. If not, 
regulatory agency has to increase the number of indicators in order to improve 
quality and efficiency.
NSAIDs present in household drug supplies, and address the issue of possible inad-
equate use. MethOds: This was an observational, cross-sectional study of drug 
storage and self-medication practice in households in the city of Novi Sad, Serbia 
over the 8 months period. Study consisted of personal insight into the drug inven-
tory, and drugs were classified according the Anatomical Therapeutic Chemical 
(ATC) classification system. Results: Out of 383 surveyed households, 280/383 
(73%) households held at least one box of NSAID in their home-pharmacy and a 
total of 473 packages of NSAID have been inventored. Most commonly encoun-
tered NSAIDs were ibuprofen (52.64%), diclofenac (31.92%), nimesulide (8.03%) and 
meloxicam (3.38%). Other NSAIDs accounted for less than 4% altogether. Over 70% 
of all NSAIDs present have been bought without prescription. Majority of ibuprfoen 
(91.3%) and diclofenac (65.74%) were obtained without a prescription even though 
in Serbia all NSAIDs (except ibuprofen 200mg) are prescription only medication 
(POM). According to European Medicine Agency, ibuprofen is classified as OTC, 
but diclofenac is strictly POM. Large amount of diclofenac used without consult-
ing a physician presents a serious issue. Nimesulide and meloxicam were almost 
exclusively bought with prescription (> 80%). cOnclusiOns: NSAIDs were pre-
sent in most of Serbian home-pharmacies and were usually bought without pre-
scription. This present a serious problem, especially for unsupervized diclofenac 
use. Financial Sources: This work was supported by the Ministry of Science and 
Technological Development, Republic of Serbia, project No. 41012.
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Objectives: to investigate changing of Candida species (C. spp) distribution and 
expenditure for antimicrobial drugs in the intensive care unit (ICU). MethOds: 
From 1.01.11 to 30.07.13 there were 200 patients with Candida spp positive samples 
in the ICU. We followed up antifungal drugs susceptibility of different C. spp. and 
evaluated expenditure for antifungal drugs. Results: C spp was detected in 200 
patients (12,2% of ICU microbiota). In 2011: 47 (19,3%); in 2012: 50 (9,3%); in 2013: 
103 (12,1%) patients. The predominant species, detected during period of inves-
tigation was Candida albicans (C.a.), which was isolated in 21 (44,7%), 21 (42%) 
and 52 (50,5%) patients in 2011,2012 and 2013 accordingly. Candida parapsilosis 
(C.p.) was on second place and frequency of this fungus detecting increased: 1 
(2,1%); 12 (24%); 31 (30,1%) patients. Candida tropicalis (C.t.) was detected: in 5 
(10,6%); 6 (12%); 10 (9,7%) patients. Candida glabrata (C.g.): in 9 (19,1%); 3 (6%); 2 
(1,9%). Candida krusei (C.k.): in 6 (12,8%); 1 (2%); 1 (1%). Candida lusitaniae (C.l.): 
in 2 (4,3%); 2 (4%); 3 (2,9%). Fluconazole susceptibility was: for C.a.: 100%; 89%; 
97%; C.t. 82%; 94%, 92%, C.g 18%; 46%; 0% in 2011, 2012 and 2013 accordingly; 
for C.p.: in 2012; 29%: in 2013: 23%. Changing of C. spp species distribution led 
to increasing of expenditure for antifungal drugs in ICU: 52% of expenditure for 
antimicrobial drugs in 2011; 72% in 2012; 78% in 2013. Echinocandines determined 
44%; 65% and 70% of ICU expenditure for antimicrobial drugs in 2011; 2012; 2013 
accordingly. cOnclusiOns: Our data coordinate with modern tendency in C. spp 
changing in ICUs. Increasing of C. spp proportion, resistant to fluconazole requires 
more frequent echinocandines use, that leads to rise of hospital expenditure.
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Objectives: The Act on the Reform of the Market for Medicinal Products (“AMNOG”) 
introduced an early benefit assessment (EBA) of pharmaceuticals in Germany in 
2011. Since the impact of the results of the EBA on a pharmaceutical’s consumption 
is unclear, those effects were quantitatively analyzed. MethOds: All pharmaceuti-
cals which were assessed by an EBA in 2011 or 2012 and were still available in 2012 
and 2013, and gliptins launched before 2011 with an EBA in 2013 were considered. A 
pharmaceutical’s real consumption (measured by defined daily doses) in 2012 and 
2013 was compared to the expected consumption (EC) based on the highest possible 
number of patients defined by the Federal Joint Committee according to a pharma-
ceutical’s label. For the EC only subpopulations with an acknowledged additional 
benefit (AB) were taken into account. Results are presented in terms of „shares“ (= 
real consumption / EC). Results: Pharmaceuticals with a low share (< 10%) were 
cabazitaxel (0.22% in 2012), saxagliptin, protease inhibitors against chronic hepatitis 
C, eribulin, vandetanib and rilpivirin. Sitagliptin, ticagrelor, antineoplastic agents 
and tafamidis achieved a midsize share (10-50%). Ivacaftor, abiraterone, emtricita-
bin/rilpivirin/tenofovir, apixaban, fingolimod and axitinib reached shares of > 50% 
and up to 398%, respectively (fingolimod in 2013). There was no correlation between 
the extent of AB and a pharmaceutical‘s share. For most pharmaceuticals consump-
tion was higher in 2013 than 2012. cOnclusiOns: The shares of pharmaceuticals 
considered in this analysis vary between 0.22% and 398%. No correlation between 
share and extent of AB could be identified. It is assumed that label restrictions 
regarding the use of a pharmaceutical, competing alternatives in the same thera-
peutic indication, a pharmaceutical’s life-cycle or overestimation of the EC influence 
a pharmaceutical’s share. Shares > 100% indicate that also subpopulations without 
an acknowledged AB receive treatment with the respective pharmaceutical. Further 
research is needed to confirm these assumptions.
PHP72
using Data enveloPment analysis (Dea) to rank gP’s accorDing to 
tHeir P4P Quality anD efficiency scores
Perronnin M., Pichetti S., Sermet C.
IRDES, Paris, France
